Chennai Meena (523489)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 6/9 suggests moderate fundamental health on selected metrics
• Reported profit growth of 14.29% shows some positive earnings momentum despite the latest quarter loss
• ROE of 58.69% indicates strong return on existing shareholder equity, though it must be verified against reported profit quality
• Small market cap of ₹27 crore in healthcare services could offer optionality if operations stabilise

Concerns

• Latest quarter net loss of ₹1 crore on sales of ₹9 crore makes current profitability negative and P/E meaningless at 0.00
• ROCE of -5.14% means the core business is not earning its cost of capital; operating quality is weak
• No promoter holding, book value, or debt/equity data creates a serious lack of transparency for a Graham-style investor
• Sales growth of only 3.17%, zero dividend yield, and price down from ₹57.48 to ₹34.47 offer little downside protection

AI Analysis

Let's start with what I can understand: Chennai Meena is a small healthcare service provider with a market cap of ₹27 crore, trading at ₹34.47. Price is closer to its 52-week low than its high. For a Graham buyer, that is often where value hides — but only if the numbers support it. Here they do not. The latest quarter shows sales of ₹9 crore and a net loss of ₹1 crore. A P/E of 0.00 is meaningless; you cannot value a stream that disappears into losses. Sales growth is a tepid 3.17%, hardly the kind of compounding that builds wealth. ROE of 58.69% might catch the eye, but with ROCE at -5.14%, the business itself is destroying value. That gap usually signals a fragile equity base or financial leverage, not operating excellence. There is no dividend, no promoter holding disclosure, no book value, and no debt data. Benjamin Graham said to invest with adequate margin of safety, not in data darkness. The Piotroski F-score of 6/9 is mildly encouraging, but one poor quarter and negative ROCE remind me that scorecards cannot replace earnings power. Profit growth of 14.29% sounds nice, but percentage improvements from a tiny base are noise. At ₹27 crore, this is a microcap without the transparency I require. I cannot calculate intrinsic value, I cannot assess moat, and I cannot trust management quality without ownership data. This is a pass. In the words of Buffett, risk comes from not knowing what you are doing. I don't know enough here, so I won't do anything.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer